Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Olstein Capital Management L.P.

Olstein Capital Management L.P. lessened its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 8.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 99,343 shares of the company’s stock after selling 9,657 shares during the period. Olstein Capital Management L.P. owned approximately 0.08% of Henry Schein worth $6,804,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HSIC. Smartleaf Asset Management LLC lifted its position in Henry Schein by 23.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock worth $52,000 after acquiring an additional 143 shares in the last quarter. Guggenheim Capital LLC raised its stake in shares of Henry Schein by 2.5% during the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company’s stock valued at $445,000 after purchasing an additional 159 shares during the period. CIBC Asset Management Inc lifted its position in shares of Henry Schein by 1.0% during the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company’s stock worth $1,235,000 after purchasing an additional 169 shares in the last quarter. Metis Global Partners LLC boosted its stake in shares of Henry Schein by 4.7% in the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company’s stock valued at $291,000 after purchasing an additional 187 shares during the period. Finally, UMB Bank n.a. boosted its stake in shares of Henry Schein by 23.2% in the first quarter. UMB Bank n.a. now owns 1,066 shares of the company’s stock valued at $73,000 after purchasing an additional 201 shares during the period. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on HSIC. Piper Sandler cut their price objective on shares of Henry Schein from $83.00 to $77.00 and set an “overweight” rating on the stock in a report on Wednesday, April 30th. Barrington Research cut their price target on Henry Schein from $90.00 to $86.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company cut their price target on Henry Schein from $80.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 6th. UBS Group dropped their price objective on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, February 26th. Finally, Wall Street Zen lowered Henry Schein from a “buy” rating to a “hold” rating in a research report on Thursday, April 17th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $79.30.

Henry Schein Stock Performance

Henry Schein stock opened at $70.37 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The company has a fifty day moving average price of $67.77 and a two-hundred day moving average price of $71.60. The company has a market cap of $8.57 billion, a PE ratio of 28.96, a P/E/G ratio of 2.13 and a beta of 0.86.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.11 by $0.04. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.24 billion. During the same period in the previous year, the business posted $1.10 EPS. The company’s quarterly revenue was down .1% on a year-over-year basis. Research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Bradford C. Connett sold 4,036 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the transaction, the chief executive officer now directly owns 62,688 shares in the company, valued at approximately $4,460,251.20. The trade was a 6.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares of the company’s stock, valued at $1,762,147.20. This trade represents a 9.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.08% of the stock is owned by corporate insiders.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.